YK-11 — Research Literature Summary
⚠ No validated human dose. This compound is not FDA-approved and has no peer-reviewed human dose-finding trials. The figures below are research conventions extrapolated from preclinical (animal/in‑vitro) and community sources — not validated clinical dosing. Treat them as study references only. Research use only; not medical advice.
Class: SARM-related myostatin modulator • Page type: research-literature reference • Updated 2026-04-23
Regulatory notice — research reference only
YK-11 is a research chemical with myostatin-modulating activity and no approved human use. No peer-reviewed human clinical trials have been published. Case reports of drug-induced liver injury have been published. This page summarizes the available preclinical literature only.
Published research summary
- YK-11 is a gene-selective androgen receptor modulator with myostatin-inhibition activity reported in mouse myoblast (C2C12) studies.
- All mechanistic data are from in vitro and mouse models. There are no peer-reviewed human PK, efficacy, or safety studies.
- Hepatotoxicity has been described in published case reports involving self-administered YK-11 products.
Why this page does not publish a consumer “cycle” schedule
No human research exists. Any consumer dosing protocol would be unsupported extrapolation.
Peer-reviewed citations
Consulting a healthcare provider: This page is a reference for published research. If you are considering any health decision, consult a licensed healthcare provider. Path to Peptides does not provide medical advice.
⚠ Before any use: human safety data is limited or absent for many of these compounds. Consult a licensed healthcare provider first — especially if you are pregnant or nursing, have a medical condition, or take other medications.